 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
0 News |  |
- Genomic mechanisms of RET inhibitor resistance in RET-fusion positive NSCLC (Section 23) - Mar 5, 2024 - Abstract #AACR2024AACR_8077;
Collectively, we show that individual RET fusion variants have distinct drug sensitivity profiles and that secondary resistance mutations are non-overlapping between RETi. The comprehensive characterization of RET-dependent mechanisms of resistance to RETi may provide therapeutic guidance for treating RET-fusion driven NSCLC and provide structural insights that can guide the development of new therapeutic regimens.
- ||| zeteletinib (BOS-172738) / Boston Pharma
Trial completion, Trial completion date, Trial primary completion date, Metastases: Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors (clinicaltrials.gov) - Oct 30, 2023
P1, N=117, Completed, Sponsor: Boston Pharmaceuticals
The comprehensive characterization of RET-dependent mechanisms of resistance to RETi may provide therapeutic guidance for treating RET-fusion driven NSCLC and provide structural insights that can guide the development of new therapeutic regimens. Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Sep 2023 | Trial primary completion date: Mar 2024 --> Sep 2023
- || zeteletinib (BOS-172738) / Boston Pharma
Trial completion date, Trial primary completion date, Metastases: Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors (clinicaltrials.gov) - May 3, 2023
P1, N=117, Active, not recruiting, Sponsor: Boston Pharmaceuticals
Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Sep 2023 | Trial primary completion date: Mar 2024 --> Sep 2023 Trial completion date: Apr 2023 --> Aug 2024 | Trial primary completion date: Apr 2023 --> Mar 2024
- || zeteletinib (BOS-172738) / Boston Pharma
Trial completion date, Trial primary completion date, Metastases: Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors (clinicaltrials.gov) - Sep 26, 2022
P1, N=117, Active, not recruiting, Sponsor: Boston Pharmaceuticals
Trial completion date: Apr 2023 --> Aug 2024 | Trial primary completion date: Apr 2023 --> Mar 2024 Trial completion date: Dec 2022 --> Apr 2023 | Trial primary completion date: Dec 2022 --> Apr 2023
- || zeteletinib (BOS-172738) / Boston Pharma
Trial completion date, Trial primary completion date, Metastases: Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors (clinicaltrials.gov) - Apr 4, 2022
P1, N=117, Active, not recruiting, Sponsor: Boston Pharmaceuticals
Trial completion date: Dec 2022 --> Apr 2023 | Trial primary completion date: Dec 2022 --> Apr 2023 Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: Jun 2022 --> Dec 2022
- || zeteletinib (BOS-172738) / Boston Pharma
Trial primary completion date, Metastases: Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors (clinicaltrials.gov) - Dec 27, 2021
P1, N=117, Active, not recruiting, Sponsor: Boston Pharmaceuticals
Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: Jun 2022 --> Dec 2022 Trial primary completion date: Dec 2021 --> Jun 2022
- || zeteletinib (BOS-172738) / Boston Pharma
Enrollment closed, Trial completion date, Metastases: Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors (clinicaltrials.gov) - Sep 16, 2021
P1, N=117, Active, not recruiting, Sponsor: Boston Pharmaceuticals
Trial primary completion date: Dec 2021 --> Jun 2022 Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Jun 2022
- ||||| BOS-172738 / Boston Pharma
P1 data: Great to see this phase 1 dose escalation data on BOS172738, a new selective RETi with preclinical activity against RET gatekeepers. ORR 31% during dose escalation. Seems highly active in #NSCLC. Anecdotal CNS activity. Looking forward to cohort expansions #ASCO21 (Twitter) - Jun 6, 2021
- ||||| BOS-172738 / Boston Pharma
Clinical: #ASCO21 BOS172738 efficacy in #RET+ cancers: RR 31% and solid waterfall plot. RR in NSCLC was 30% and RR in MTC was 44%. Some were quite durable, including one MTC at 659+ days. Also showed some CNS activity which is important. (Twitter) - Jun 5, 2021
- |||||| BOS-172738 / Boston Pharma
Clinical, P1 data: #ASCO21 Presented here are the BOS172738 phase I escalation data. Included 34 pts with #RET fusion positive NSCLC and 21 pts with MTC. 28% had prior multi-kinase inhibitor. Didn't specify but unlikely that any had prior selective inhibitor. (Twitter) - Jun 5, 2021
- ||||| BOS-172738 / Boston Pharma
Clinical: New RET-blocking drug, BOS172738, shows activity in Ph1 clinical trials with RET-altered #NSCLC & thyroid cancer. Great to see more options but too early to say whether response rate data will meet the benchmark. @schoffski of @UZLeuven @RETpositive #LCSM #ASCO21 (Twitter) - Jun 4, 2021
- ||||| BOS-172738 / Boston Pharma
@schoffski of @UZLeuven talks on the Phase I results of BOS172738, a highly potent and selective RET inhibitor at #ASCO21 Learn more now 👉https://t.co/fBCbhRnLVm👈 @VJOncology @ASCO @OncoAlert #LCsm #OncoAlert (Twitter) - Jun 4, 2021
- |||| BOS-172738 / Boston Pharma
RET inhibitors still an evolving story with @schoffski presenting promising data w/ BOS172738 @BosPharma #ASCO21 #RET @BandVsCancer @BurrisSkip (Twitter) - Jun 4, 2021
- |||||| BOS-172738 / Boston Pharma
P1 data: Good activity of selective RET inhibitor BOS172738 in RET-driven tumors, such as RET-fusion NSCLC & RET-mutated medullary thyroid carcinoma, presented during Developmental Therapeutics session at ASCO today. Really like Phase 1 trial where waterfall plots remind me of waterfalls (Twitter) - Jun 4, 2021
- zeteletinib (BOS-172738) / Boston Pharma
[VIRTUAL] Lambert-Eaton-Myasthenic-Syndrome as an adverse effect of RET inhibitor therapy: a case report (Room Paris) - May 30, 2021 - Abstract #EAN2021EAN_990;
As far as we know, this is the first described case suggesting an association between RET inhibitor therapy, a novel treatment for advanced tumors with RET gene alterations, and LEMS. Physicians should be aware of this possible adverse effect in patients who develop muscle weakness while undergoing RET inhibitor therapy.
- |||||| BOS-172738 / Boston Pharma
Clinical: Highly target-specific next generation RET inhibitor BOS172738 showing good safety and impressive activity in RET-altered solid tumors such as RET-fusion non-small cell lung cancer, RET-mutated medullary thyroid cancer and others. Read Schöffski et al. https://t.co/Iixy0KEOTe (Twitter) - May 20, 2021
- BOS-172738 / Boston Pharma
[VIRTUAL] BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_813;
P1
BOS172738 is a highly potent and selective RET inhibitor with a differentiated safety profile and clinical activity against RET-altered tumors, including patients with brain metastases . BOS172738 continues to be evaluated in patients with NSCLC, MTC, and in patients previously treated with other selective RET inhibitors.
- || zeteletinib (BOS-172738) / Boston Pharma
Trial completion date, Trial primary completion date, Metastases: Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors (clinicaltrials.gov) - Sep 2, 2020
P1, N=114, Recruiting, Sponsor: Boston Pharmaceuticals
BOS172738 continues to be evaluated in patients with NSCLC, MTC, and in patients previously treated with other selective RET inhibitors. Trial completion date: Jun 2021 --> Nov 2021 | Trial primary completion date: Dec 2020 --> Nov 2021
- || zeteletinib (BOS-172738) / Boston Pharma
Trial completion date, Trial primary completion date, Metastases: Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors (clinicaltrials.gov) - May 5, 2020
P1, N=114, Recruiting, Sponsor: Boston Pharmaceuticals
Trial completion date: Jun 2021 --> Nov 2021 | Trial primary completion date: Dec 2020 --> Nov 2021 Trial completion date: Nov 2020 --> Jun 2021 | Trial primary completion date: May 2020 --> Dec 2020
- ||| zeteletinib (BOS-172738) / Boston Pharma
New P1 trial, Metastases: Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors (clinicaltrials.gov) - Dec 19, 2018
P1, N=114, Recruiting, Sponsor: Boston Pharmaceuticals